Home > Journals > Minerva Endocrinologica > Past Issues > Articles online first > Minerva Endocrinologica 2016 Oct 28



Cite this article as


A Journal on Endocrine System Diseases

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,383



Minerva Endocrinologica 2016 Oct 28


language: English

An up-todate on the methabolic syndrome’s epigenomic risk

Rosanna PERRICONE 1, Antonio PIZZUTI 2

1 Dipartimento di Scienze Cardiologiche, Nefrologiche, Anestesiologiche e Geriatriche dell’Università di Roma “La Sapienza”, Facoltà di Medicina e Odontoiatria, Roma, Italy; 2 Dipartimento di Medicina Sperimentale dell’Università di Roma “La Sapienza”, Facoltà di Medicina e Odontoiatria, Roma, Italy


The primitive genome’s and the individual phenotype’s modifications by epygenesys surveyes are crucial to evaluate the methabolic syndrome risk and its prevention. Through the most recent surveys, this analysis is aimed to several processes by which the various epigenetic types who are different from one to another subject may act on the methabolism key-genes, like that they even indirectly arouse the straight onset of one or more methabolic syndromes: the risk of passing this syndrome to next offsprings is more or less high. Through the new later surveyes who are originated from analysis undertaken on animals and experiments on men by in vitro and in vivo test on has proved how much the epigenetic modifications are affected either by the environmental compounds, often going back to maternal and prenatal nourishment, or by the more or less strong connection to the transcriptional genetic control : this occurs to the stochastic eventuality to pass the methabolic syndrome phenotype’s to the following cohorts. Mainly in an individual observation these risks evaluation is until now indefined, buti t is going in progress and one has still waiting the issues of next new performed surveyes to can enlight on some interconnection that is following the histonic methilation and the micro-RNA not codifyng control role on some gene who is involved in these methabolic syndromes; this process is variable from one to another subject. All in conclusion is aiming to carry out the pharmacological treatment of the primary prevention to the methabolic diseases risk.

top of page

Publication History

Cite this article as

Perricone R, Pizzuti A. An up-todate on the methabolic syndrome’s epigenomic risk. Minerva Endocrinol 2016 Oct 28. 

Corresponding author e-mail